Press coverage about Zogenix (NASDAQ:ZGNX) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Zogenix earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.7504802703983 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Daily Insider Ratings Round Up 10/3/17: ZGNX, SOR – Seeking Alpha (seekingalpha.com)
- ETFs with exposure to Zogenix, Inc. : October 5, 2017 (finance.yahoo.com)
- Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares (finance.yahoo.com)
- Q3 2017 Earnings Forecast for Zogenix, Inc. (ZGNX) Issued By Leerink Swann (americanbankingnews.com)
A number of brokerages have recently commented on ZGNX. Leerink Swann reaffirmed an “outperform” rating and issued a $50.00 price target (up from $20.00) on shares of Zogenix in a report on Monday, October 2nd. ValuEngine raised Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $55.00 price target (up from $26.00) on shares of Zogenix in a report on Friday, September 29th. William Blair raised Zogenix from a “market perform” rating to an “outperform” rating in a report on Friday, September 29th. Finally, Mizuho reaffirmed a “buy” rating and issued a $51.00 price target (up from $28.00) on shares of Zogenix in a report on Friday, September 29th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $40.00.
Shares of Zogenix (NASDAQ:ZGNX) opened at 39.85 on Friday. Zogenix has a 1-year low of $7.50 and a 1-year high of $41.80. The company’s 50 day moving average price is $20.91 and its 200-day moving average price is $14.68. The firm’s market cap is $989.91 million.
Zogenix (NASDAQ:ZGNX) last issued its earnings results on Tuesday, August 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.01). Zogenix had a negative return on equity of 70.75% and a negative net margin of 309.76%. The company had revenue of $7.10 million during the quarter, compared to analyst estimates of $3.48 million. During the same quarter in the previous year, the firm earned ($0.76) earnings per share. The business’s revenue was up 238.1% compared to the same quarter last year. Equities analysts expect that Zogenix will post ($3.62) EPS for the current fiscal year.
In other news, major shareholder Life Sciences Maste Perceptive bought 222,055 shares of the stock in a transaction on Friday, September 29th. The shares were purchased at an average price of $32.83 per share, for a total transaction of $7,290,065.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.00% of the company’s stock.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.